Expression pattern of the von Hippel-Lindau protein in human tissues

Laboratory Investigation

Volumn 75, Issue 2, 1996, Pages 231-238

  Los, Maartje ^a   Jansen, Gerard H ^a   Kaelin, William G ^b   Lips, Cornelis J M ^a   Blijham, Geert H ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; RNA POLYMERASE II; UNCLASSIFIED DRUG; VON HIPPEL LANDAU PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CELLULAR DISTRIBUTION; ENZYME REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; CYTOPLASM; DISEASE SUSCEPTIBILITY; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; LIGASES; NEURONS; ORGAN SPECIFICITY; PHEOCHROMOCYTOMA; PROTEIN BIOSYNTHESIS; PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0029772338     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Aso T, Lane WS, Conaway JW, and Conaway RC (1995). Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II. Science 269:1439-1443.
2. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, and Zbar B (1995). Germ-line mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5:66-75.
3. Dameron KM, Volpert OV, Tainsky MA, and Bouck N (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584.
4. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, and Klausner RD (1995a). Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 92:6459-6463.
5. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, and Klausner RD (1995b). Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406.
6. Foster K, Osborne RJ, Huddart RA, Affara NA, Ferguson Smith MA, and Maher ER (1995). Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. Eur J Cancer 31A:2392-2395.
7. Gnarra JR, Lerman MI, Zbar B, and Linehan WM (1995). Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22:3-8.
8. Hibi K, Takahashi T, and Yamakawa K (1992). Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445-449.
9. Iliopoulos O, Kibel A, Gray S, and Kaelin WG (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826.
10. Kanters SDJM, Lammers J-WJ, and Voest EE (1995). Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8:1389-1397.
11. Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Höppener JW, and Lips CJM (1994). Von Hippel-Lindau disease: New strategies in early detection and treatment. Am J Med 97:158-168.
12. Kessler PM, Vasavada SP, Rackley RR, Stackhouse T, Duh FM, Latif F, Lerman MI, Zbar B, and Williams BG (1995). Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1:457-466.
13. Kibel A, Iliopoulos O, Decaprio JA, and Kaelin WG (1995). Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446.
14. Knudson AG (1993). Anticoncogenes and human cancer. Proc Natl Acad Sci USA 90:10914-10921.
15. Knudson AG (1995). VHL gene mutations and clear cell renal carcinomas. Sci Am 1:180-181.
16. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wie MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Schmidt MA, Le Pâslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, and Lerman MI (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
17. Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, and Klausner RD (1996). Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 93: 1770-1775.
18. Lindau A (1926). Studien über Kleinhirnzysten: Bau Pathogenese und Beziehungen zur Angiomatosis retinae. Acta Pathol Microbiol Scand Suppl II:1-129.
19. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson Smith MA, and Morton N (1991). Von Hippel-Lindau disease: A genetic study. J Med Genet 28:443-447.
20. Mukhopadhyay D, Tsiokas L, and Sukhatme VP (1995). Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165.
21. Neumann HPH, Lips CJM, Hsia YE, and Zbar B (1995). Von Hippel-Lindau syndrome. Brain Pathol 5:181-193.
22. Russel DS and Rubinstein LJ (1989). Pathology of tumours of the nervous system. London: Edward Arnold.
23. Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling-Katz M, Seizinger B, Nakamura Y, White R, Marshall FF, Lerman MI, and Zbar B (1989). Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097-1101.
24. von Hippel E (1911). Die anatomische Grundlage der von mir beschriebenen sehr seltenen Erkrankung der Netzhaut. Albrecht von Graefes Arch Ophthalmol 79:350-377.
25. von Hippel E (1904). Über eine sehr seltene Erkrankung der Netzhaut. Albrecht von Graefes Arch Ophthalmol 59:83-86.
26. Waber PG, Lee NK, and Nisen PD (1996). Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer. Oncogene 12:365-369.
27. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, Neumann HP, Laidlaw J, Li FP, Klein-Szanto AJP, Seizinger BR, and Kley N (1994). Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092-1102.
28. Wizigmann-Voos S, Breier G, Risau W, and Plate KH (1995). Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364.
29. Yokoyama S, Yamakawa K, Tsuchiya E, Murata M, Sakiyama S, and Nakamura Y (1992). Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 52:873-877.
30. Zhuang ZP, Emmertbuck MR, Roth MJ, Gnarra J, Linehan WM, Liotta LA, and Lubensky IA (1996). Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 27:152-156.